Patents by Inventor Maria Carlsen MELANDER

Maria Carlsen MELANDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapies targeting PD-1, TIM-3, and LAG-3
    Patent number: 11939380
    Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: March 26, 2024
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • Anti-AXL antibodies and compositions
    Patent number: 11807688
    Abstract: This invention relates to anti-AXL antibodies and methods of using them in treating diseases and conditions related to AXL activity, e.g., cancer.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: November 7, 2023
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Torben Gjetting, Trine Lindsted, Anton Willer, Anne Worsaae, Maria Carlsen Melander, Janus Schou Jakobsen, Randi Westh Hansen
  • COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3
    Publication number: 20220380470
    Abstract: This invention relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the invention are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Application
    Filed: June 7, 2022
    Publication date: December 1, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • ANTI-FLT3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20210317216
    Abstract: This invention relates to anti-FLT3 antibodies and methods of using them in enhancing immunity in a patient in need thereof and in treating cancer.
    Type: Application
    Filed: April 14, 2021
    Publication date: October 14, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Trine Lindsted, Maria Carlsen Melander, Matteo Riva, Mikkel Wandahl Pedersen, Randi Westh HANSEN
  • Anti-AXL Antibodies and Compositions
    Publication number: 20210269532
    Abstract: This invention relates to anti-AXL antibodies and methods of using them in treating diseases and conditions related to AXL activity, e.g., cancer.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 2, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Torben GJETTING, Trine LINDSTED, Anton WILLER, Anne WORSAAE, Maria Carlsen MELANDER, Janus Schou JAKOBSEN, Randi Westh HANSEN
  • COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3
    Publication number: 20200407444
    Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Application
    Filed: April 5, 2018
    Publication date: December 31, 2020
    Applicant: SYMPHOGEN A/S
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak